Drug-eluting stents for cardiovascular disorders

被引：12

作者：

Juan F. Granada

Grzegorz L. Kaluza

Albert Raizner

机构：

[1] The Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, TX 77030

来源：

Current Atherosclerosis Reports | 2003年 / 5卷 / 4期

关键词：

Paclitaxel; Sirolimus; Major Adverse Cardiac Event; Neointimal Formation; Restenosis Rate;

D O I：

10.1007/s11883-003-0054-6

中图分类号：

学科分类号：

摘要：

Drug-eluting stents have emerged in recent years as a very promising therapy for prevention of restenosis after coronary implantation. Early randomized, clinical trials have suggested that stents eluting drugs, such as paclitaxel or sirolimus, released from polymeric and nonpolymeric coatings, are able to reduce restenosis in simple de novo lesions by more than 80% in comparison with bare metal stents. If restenosis can be indeed minimized globally by drug-eluting stents, coronary revascularization may expand to patients and lesions currently not considered for percutaneous intervention because of excessive recurrence, and may open possibilities for other stent-based endovascular treatments of atherosclerosis. Copyright © 2003 by Current Science Inc.

引用

页码：308 / 316

页数：8

共 48 条

[1]

Mintz G.S., Popma J.J., Pichard A.D., Et al., Arterial remodeling after coronary angioplasty: A serial intravascular ultrasound study, Circulation, 94, pp. 35-43, (1996)

[2]

Hoffmann R., Mintz G.S., Dussaillant G.R., Et al., Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study, Circulation, 94, pp. 1247-1254, (1996)

[3]

Kastrati A., Mehilli J., Dirschinger J., Et al., Restenosis after coronary placement of various stent types, Am. J. Cardiol., 87, pp. 34-39, (2001)

[4]

Lansky A.J., Roubin G.S., O'Shaughnessy C.D., Et al., Randomized comparison of GR-II stent and Palmaz-Schatz stent for elective treatment of coronary stenoses, Circulation, 102, pp. 1364-1368, (2000)

[5]

Kastrati A., Mehilli J., Dirschinger J., Et al., Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO) trial, Circulation, 103, pp. 2816-2821, (2001)

[6]

Finkelstein A., McClean D., Kar S., Et al., Local drug delivery via a coronary stent with programmable release pharmacokinetics, Circulation, 107, pp. 777-784, (2003)

[7]

van der Giessen W.J., Lincoff A.M., Schwartz R.S., Et al., Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries, Circulation, 94, pp. 1690-1697, (1996)

[8]

Drachman D.E., Edelman E.R., Seifert P., Et al., Neointimal thickening after stent delivery of paclitaxel: Change in composition and arrest of growth over six months, J. Am. Coll. Cardiol., 36, pp. 2325-2332, (2000)

[9]

Suzuki T., Kopia G., Hayashi S., Et al., Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model, Circulation, 104, pp. 1188-1193, (2001)

[10]

Mohacsi P.J., Tuller D., Hulliger B., Et al., Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor, J. Heart Lung Transplant., 16, pp. 484-492, (1997)

← 1 2 3 4 5 →